Clinical utility of TGFB1 and its receptors ( TGFBR1 and TGFBR2 ) in thyroid nodules: evaluation based on single nucleotide polymorphisms and mRNA analysis

• Published in: Archives of Endocrinology and Metabolism Vol. 65; no. 2; pp. 172 - 184
• Main Authors: Peres, Karina Colombera, Teodoro, Larissa, Amaral, Laís Helena Pereira, Teixeira, Elisângela Souza, Barreto, Icléia Siqueira, de Freitas, Leandro Luiz Lopes, Maximo, Valdemar, Assumpção, Lígia V Montalli, Bufalo, Natassia Elena, Ward, Laura Sterian
• Format: Journal Article
• Language: English
• Published: Brazil Sociedade Brasileira de Endocrinologia e Metabologia 01.03.2021; Brazilian Society of Endocrinology and Metabolism
• Subjects: Humans; mRNA expression; Original; polymorphism; Polymorphism, Single Nucleotide; Receptor, Transforming Growth Factor-beta Type I - genetics; Receptor, Transforming Growth Factor-beta Type II - genetics; RNA, Messenger - genetics; Thyroid cancer; Thyroid Neoplasms; Thyroid Nodule - genetics; Transforming Growth Factor beta1 - genetics; transforming growth factor-β; Tumor Microenvironment; polymorphism; Thyroid cancer; transforming growth factor-β; mRNA expression
• ISSN: 2359-3997; 2359-4292
• DOI: 10.20945/2359-3997000000330

Abnormalities involving the gene and its receptors are common in several types of cancer and often related to tumor progression. We investigated the role of single nucleotide polymorphisms (SNP) in the susceptibility to cancer, their impact on its features, as well as the role of mRNA expression of these genes in thyroid malignancy. We genotyped , , and SNPs in 157 papillary thyroid cancer (PTC) patients and 200 healthy controls. Further, we investigated RNA samples of 47 PTC and 80 benign nodules, searching for differential mRNA expression. SNPs rs1800472 and rs1800469 were associated with characteristics of PTC aggressiveness. Effect predictor software analysis of nonsynonymous SNP rs1800472 indicated increasing protein stability and post-translational changes. mRNA expression was upregulated in PTC and downregulated in benign samples, differentiating malignant from benign nodules (p<0.0001); PTC from goiter (p<0.0001); and PTC from FA (p<0.0001). mRNA expression was upregulated in goiter and PTC, but downregulated in FA, distinguishing PTC from goiter (p=0.0049); PTC from FA (p<0.0001); and goiter from FA (p=0.0267). On the other hand, was downregulated in all histological types analyzed and was not able to differentiate thyroid nodules. polymorphism rs1800472 may confer greater activity to TGF-β1 in the tumor microenvironment, favoring PTC aggressiveness. Evaluation of and mRNA levels may be useful to identify malignancy in thyroid nodules.